

7. Literaturverzeichnis

1. Beck W.T., Grogan T.M., Cheryl L. et al.: Methods to detect P-Glycoprotein-associated multidrug resistance in patients' tumors: Consensus Recommendations. *Cancer Res.* 1996: 56(1): 3010-3020.
2. Charpin C., Vielh P., Duffaud F. et al.: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. *J. Natl Cancer Inst.* 1994 : 86(20): 1539-45.
3. Chen C.-J., Chin J.E., Ueda K. et al.: Internal duplication and homology with bacterial transport proteins in the *mdr1* (P-Glycoprotein) gene from multidrug resistant human cells. *Cell* 1986: 47: 381-389.
4. Chin J.E., Soffrir R., Noonan K.E. et al.: Structure and expression of the human MDR (P-glycoprotein) gene family. *Mol. Cell. Biol.* 1989: 9: 3808.
5. Chin K.-V., Pastan I. and Gottesmann M.M. et al.: Function and regulation of the human multidrug resistance gene. *Adv. Cancer Res.* 1993: 60: 157-180.
6. Chugani D.C., Rome L.H. and Kedersha N.L.: Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. *J. Cell. Sci.* 1993: 106: 23-29.
7. Cole S.P.C., Bhardway G., Gerlach J.H. et al.: Overexpression of a transporter gene in a multidrug resistant human cancer lung cell line. *Science* 1992: 258: 1650-1654.
8. Cole S.P.C. and Deeley R.G.: Multidrug resistance-associated protein: sequence correction. *Science* 1993: 260: 879.
9. Cole S.P.C., Sparks K.E., Fraser K. et al.: Pharmacological characterisation of multidrug resistant MRP-transfected human tumor cells. *Cancer Res.* 1994: 54: 5902-5910.
10. Coley H.M., Amos W.B., Twentyman P.R. et al.: Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cells. *Br. J. Cancer* 1993: 67: 1316-1323.
11. Cordell J.L., Falini B., Erber W.N. et al.: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti

- alkaline phosphatase (APAAP complexes). *J. Histochem.Cytochem.* 1984: 32(2): 219-229.
12. Cordon-Cardo C., O'Brien J.P., Boccia J. et.al.: Expression of the multidrug resistance gene product (P-Glycoprotein) in human normal and tumor tissues. *J. Histochem. Cytochem.*, 1990: 38 (9): 1277-1287.
 13. Cornwell M.M., Pastan I. and Gottesmann M.M.: Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. *J. Biol. Chem.* 1987: 262: 2166-2170.
 14. Devault A. and Gros P.: Two members of the mouse *mdr* gene family confer multidrug resistance with overlapping but distinct drug specificities. *Mol. Cell. Biol.* 1990: 10: 1652-1663.
 15. Eijdens E.W., de Haas M., Coc-Martin J.M. et al. : Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. *Int. J. Cancer* 1995: 60: 676-684.
 16. Emig M., Sauße S., Wittor H. et al.: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT- PCR. *Leukemia* 1999: 13: 1825-1832.
 17. Endicott JA, Sarangi F. and Ling V.: Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. *DNA Seq.* 1991: 2: 89-101.
 18. Filipitis M, Suchomel RW, Zöchbauer S et al.: Clinical relevance of drug resistance genes in malignant diseases. *Leukemia* 1996: 10: Suppl.3: 10-17.
 19. Gervasoni J.E.Jr., Fields S.Z., Krishna S. et.al.: Subcellular distribution of Daunorubicin in P-Glycoprotein-positive and -negative drug resistant cell lines using laser-assisted confocal microscopy. *Cancer Res.* 1991: 51: 4955-4963.
 20. Grant C.E., Valdimarsson G., Hipfner D.R.: Overexpression of multidrug resistance-associated protein (MRP). Increases resistance to natural product drugs. *Cancer Res.* 1994: 54: 357-361
 21. Gros P., Neria Y., Croop J.M. et.al.: Isolation and expression of a complementary DNA that confers multidrug resistance. *Nature* 1986: 323: 728-731.
 22. Gros P., Croop J. and Housman D.E.: Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. *Cell* 1986: 47: 371-380.

23. Gurbuxani S., Zhou D. Simonin G. et. al.: Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. *Ann. Hematol.* 1998: 76: 195-200.
24. Hamada H., Hagiwara K.-I., Nakajima T. et.al.: Phosphorylation of the Mr 170 000 to 180 000 glycoprotein specific to multidrug resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. *Cancer Res.* 1987: 47: 2860-2865.
25. Hart S.M., Ganeshaguru K., Hoffbrand A.V. et.al.: Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. *Leukemia* 1994: 8 (1): 2163-2168.
26. Hart S.M., Ganeshaguru K., Scheper R.J. et.al.: Expression of the human major vault protein LRP in acute myeloid leukemia. *Exp. Hematol.* 1997: 25: 1227-1232.
27. Hermann C., Volkandt W., Wittich B. et al.: The major vault protein (MVP100) is contained in cholinerg nerve terminals of electric ray organ. *J. Biol. Chem.* 1996: 271: 13908-13915.
28. Higgins C.F.: ABC tansporters: from microorganisms to man. *Annu. Rev. Cell. Biol.* 1992: 8: 67-113.
29. Hindenburg A.A., Gervasoni J.E. Jr., Krishna S. et al.: Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and –resistant HL-60 cells. *Cancer Res.* 1989: 49: 4607-4614.
30. Hsu S., Lothstein L. and Horwitz S.: Differential overexpression of three mdr gene family members in multidrug resistant J774.2 mouse cells. *J. Biol. Chem.* 1989: 264: 12053-12062.
31. Ikeda K., Oka M., Yamada Y. et al.: Adult t-cell leukemia cells overexpress the multidrug resistance protein (MRP) and lung-resistance protein (LRP) genes. *Int. J. Cancer* 1999: 82: 599-604.
32. Inaba M., Nagashima K., Sakurai Y. et al.: Reversal of multidrug resistance by non-antitumor anthracycline analogues. *Gann* 1984: 75: 1049-1052.
33. Inaba M. and Nagashima K.: Non-antitumor Vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro. *Jpn. J. Cancer Res.* 1986: 77: 197-204.
34. Izquierdo M.A., Scheffer G.L., Flens M.J. et.al.: Broad distribution of the multidrug resistance-related vault lung-resistance protein in normal human tissues and tumors. *Am. J. Pathol.* 1996a: 148 (3): 877-887.

35. Izquierdo M.A., Shoemaker R.H., Flens M.J. et.al.: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. *Int. J. Cancer* 1996b: 65: 230-237.
36. Izquierdo M.A., Scheffer G.L., Flens M.J. et al.: Major vault protein LRP-related multidrug resistance. *Eur. J. Cancer* 1996c: 32A: 979-984.
37. Jedlitschky G., Leier I., Bucholz U. et al.: ATP dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. *Cancer Res.* 1994: 54: 4833.
38. Jedlitschky G., Leier I., Buchholz U. et al.: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gen encoded conjugate export pump. *Cancer Res.* 1996: 56: 988-994.
39. Juliano R.L. and Ling V.: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta* 1976 Nov 11;455(1):152-62
40. Kedersha N.L. and Rome L.H.: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. *J. Cell. Biol.* 1986: 103: 699-709.
41. Kedersha N.L., Miquel M.C., Bittner D. et al.: Vaults II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. *J. Cell Biol.* 1990: 110: 895-901.
42. Kedersha N.L., Heuser J.E. Chugani, et.al.: Vaults III. Vault ribonucleoprotein particles open into a flower-like structures with octagonal symmetry. *J. Cell. Biol.* 1991: 112: 225-235.
43. Kickhoefer V.A., Searles R.P., Kedersha N.L. et al.: Vault ribonucleoprotein particles from rat and bullfrog contain related small RNA that is described by RNA polymerase III. *J. Biol. Chem.* 1993: 268: 7868-7873.
44. Kool M., de Haas M., Scheffer G.L. et al. : Analysis of expression of MOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated gene (MRP1), in human cancer cell lines. *Cancer Res.* 1997: 57: 3537-3547.
45. Kruh G.D., Chan A., Myers K. et al.: Expression complementary DNA library transfer establishes MRP as a multidrug resistance gene. *Cancer Res.* 1994: 54: 1649-1652.

46. Lautier D., Canitrot Y., Deeley R.G. et al.: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. *Biochem. Pharmacol.* 1996; 52: 967-977.
47. Legrand O., Perrot J.-Y., Tang R.P. et al.: Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. *Br J Haematol.* 1996; 94: 23-33.
48. Legrand O., Simonin G., Zittoun R. et al.: Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. *Leukemia* 1998; 12: 1367-1374.
49. Leier I., Jedlitschky G., Buchholz U. et al.: The MRP gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates. *J. Biol. Chem.* 1994; 269: 27807-27810.
50. Leier I., Jedlitschky G., Buchholz U. et al.: The MRP gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates. *J. Biol. Chem.* 1994; 269: 45: 27807-27810.
51. Leier I., Jedlitschky G., Buchholz U. et al.: ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. *Biochem. J.* 1996; 314: 433-437.
52. List A.F. : Non-P-glycoprotein drug export mechanisms of multidrug resistance. *Sem. Haematology* 1997; 34 (4): Suppl. 5: 20-24
53. Loe D.W., Deeley R.G. and Cole, S.P.C.: Biology of the multidrug resistance-associated protein, MRP. *Eur. J. Cancer* 1996; 32A: 6: 945-957.
54. Lohri A, van Hille B, Bacchi M et al.: Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II α) in 57 newly diagnosed acute myeloid leukemias. *Eur. J. Hematol.* 1997; 59: 206-215.
55. Malayeri R, Filipitis M, Suchomel W et al.: Multidrug resistance in leukemias and its reversal. *Leukemia and Lymphoma* 1996; 23: 451-458.
56. Meijer G.A., Schroeijers A.B., Flens M.J. et al.: Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. *J. Clin. Pathol.* 1999; 52: 450-454.

57. Meschini S., Calabrini A., Monti E. et al.: Intracellular P-Glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. *Int. J. Cancer* 2000; 87: 615-628.
58. Michieli M., Damiani D., Ermacora A. et al.: P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: biological and clinical implications. *Br. J. Haematol.* 1999; 104: 328-335.
59. Muller M., Meijer C., Zaman G.J.R. et al.: Overexpression of the gene encoding the multidrug resistance associated protein results in increased ATP dependent glutathione S-conjugate transport. *Proc. Natl. Acad.Sci. USA* 1994; 91: 13033-13037.
60. Nakagawa M., Akiyama S., Yamaguchi T. et al.: Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. *Cancer Res.* 1986; 46: 4453-4457.
61. Nitsche A., Steuer N., Schmidt C.A. et al.: Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. *Clin. Chem.* 1999; 45:11: 1932-1937
62. Nooter K., Westerman A.M., Flens M.J. et al.: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. *Clin. Cancer Res.* 1995; 1: 1301-1310.
63. Pall G., Spitaler M., Hofmann J. et al.: Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. *Leukemia* 1997; 11: 1067-1072.
64. Paulusma C.C., Bosma P.J., Zaman G.J.R. et al.: Congenital jaundice in rats with mutation in a multidrug resistance-associated protein gene. *Science* 1996; 271: 1126-1128.
65. Ramu A., Glaubiger D. and Fuks Z.: Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. *Cancer Res.* 1984; 44: 4392-4395.
66. Raymond M., Rose E., Housman D. et.al.: Physical mapping, amplification and overexpression of the mouse *mdr* gene family in multidrug resistant cells. *Mol. Cell. Biol.* 1990; 10: 1642-1651.
67. Riordan J.R., Deuchars K., Kartner N. et al.: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. *Nature* 1985; 316: 817-819.

68. Rome L., Kedersha N., Chugani D.: Unlocking vaults: organelles in search of a function. *Trends Cell Biol.* 1991: 1: 47-50.
69. Saiki R.K., Scharf S., Faloona F. et al.: Enzymatic amplification of β -globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 1985: 230: 1350-1354.
70. Scheffer G.L, Wijngaard P.L.J., Flens M.J. et. al.: The drug resistance -related protein LRP is the human major vault protein. *Nature Medicine* 1995: 1 (6)
71. Scheper R.J., Broxtermann H.J., Scheffer G.L. et. al.: Overexpression of a M 110,000 vesicular protein in non P-Glycoprotein-mediated multidrug resistance. *Cancer Res.* 1993: 53: 1475-1479.
72. Schneider E., Cowan K.H., Bader H. et. al. : Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. *Blood* 1995: 85 (1): 186-193.
73. Schroeijers A.B., Scheffer G.L., Flens M.J. et al.: Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. *Am J Pathol.* 1998: 152: 373-378.
74. Schumpelick V., Bleese N.M. und Mommsen U.: *Chirurgie.* Ferdinand Enke Verlag Stuttgart 1994.
75. Schuurhuis G.H., Broxterman H.J., Cervantes A. et al.: Quantitative determination of factors contributing to doxorubicin resistance in multidrug resistant cells. *J.Natl.Cancer Inst.* 1989: 81: 1887-1892.
76. Shen D.W., Fojo A., Chin J.E. et al.: Human multidrug-resistant cell lines: increased *mdr1* expression can precede gene amplification. *Science* 1986: 232: 643-645.
77. Shiraishi N., Akiyama S., Kobayashi M. et.al.: Lysosomotropic agents reverse multiple drug resistance in human cancer cells. *Cancer Letters* 1986: 30: 251-259.
78. Slater L.M., Sweet P., Stupecky M. et.al.: Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphoma leukemia in vitro. *J. Clin. Invest.* 1986: 77:1405-1408.
79. Slovak M.L., Pelkey H.-J., Cole S.P.C. et al.: The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. *Caner Res.* 1995: 55: 4214-4219.

80. Spoelstra E.C., Dekker H., Schuurhuis G.J. et al.: P-Glycoprotein drug efflux pump involved in the mechanism of intrinsic drug resistance in various colon cancer cell lines. *Biochem. Pharm.* 1991; 41: 3: 349-359.
81. Statistisches Bundesamt (Hrsg.): Statistisches Jahrbuch 1992 für die Bundesrepublik Deutschland. Metzler-Poeschel, Wiesbaden 1992.
82. Sugawara I., Akiyama S., Scheper R.J. et.al.: Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. *Cancer Lett.* 1997; 112: 23-31.
83. Tsuruo T., Iida H. Tsukagoshi S. et.al.: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristin and vinblastin by verapamil. *Cancer Res.* 1981; 41: 1967-1972.
84. Tsuruo T., Iida H., Tsukagoshi S. et.al.: Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. *Cancer Res.* 1982; 42: 4730-4733.
85. Ueda K., Cornwell M., Gottesmann M. et al.: The *mdr1* gene, responsible for multidrug resistance, codes for P-glycoprotein. *Biochem. Biophys. Res. Comm.* 1986; 141: 956-962.
86. Ueda K., Cardarelli C., Gottesman M.M. et.al.: Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastin. *Proc. Natl. Acad. Sci. USA* 1987; 84: 3004-3008.
87. Van der Valk P., van Kalken C.K. et.al.: Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. *Ann. Oncol.* 1990; 1: 56-64
88. Váradi A., Tisdády G.E., Bakos E. et.al.: Membrane topology of the human multidrug resistance-associated protein (MRP) and its homologs. *Cytotech.* 1998; 27: 71-79.
89. Vasu S.K. and Rome L.H.: Disruption of the major proteins reveals growth and morphological defects and uncovers a new associated protein. *J. Biol. Chem.* 1995; 270: 16588-16594.
90. Xu D., Areström I., Virtala R. et al.: High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. *Br J Haematol.* 1999; 106: 627-633.

91. Zaman G.J.R., Versantvoort C.H.M. et.al.: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. *Cancer Res.* 1993; 53: 1747-1750.
92. Zaman G.J.R., Flens M.J., van Leusden M.R. et al.: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. *Proc. Natl. Acad.Sci. USA* 1994; 91: 8822-8826.
93. Zamora J.M. and Beck W.T.: Chloroquine enhancement of anticancer drug cytotoxicity in drug resistant human leukemic cells. *Biochem. Pharmacol.* 1986; 35: 4303-4310.
94. Zhou D.-C., Zittoun R. and Marie J.-P.: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. *Leukemia* 1995; 9: 1661-1666.